NEW YORK — Paige and Flagship Biosciences said on Thursday that they have signed an agreement to integrate certain of their digital pathology technologies for immune-oncology biomarker analysis.
Under the terms of the deal, Flagship's TissueInsight artificial intelligence-based software for quantifying PD-L1 expression in immunohistochemistry tissue samples will be made available directly through the Paige Platform, Paige's digital pathology software system.
Financial and other terms were not disclosed.
"Immunohistochemistry scoring of PD-L1 has traditionally been a time-consuming, manual process that is subject to variability between pathologists," David Klimstra, Paige's founder and chief medical officer, said in a statement. "TissueInsight augments our native Paige capabilities by providing an easy-to-use and accurate software that produces more information of clinical value than can be generated manually."
Earlier this week, Paige inked an agreement to offer Mindpeak's BreastIHC AI-based tool for breast cancer analysis through the Paige Platform.